Search results for "IPR"

showing 10 items of 1515 documents

Potential Myocardial Iron Content Evaluation by Magnetic Resonance Imaging in Thalassemia Major Patients Treated with Deferoxamine or Deferiprone Dur…

2003

The purpose of this study was to evaluate if the variations of heart magnetic resonance imaging in beta-thalassemia major patients treated with Deferoxamine B mesylate (DF) or Deferiprone (L1) chelation therapy is a useful tool of the indirect myocardial iron content determination. For this reason, a prospective study was carried out. Seventy-two consecutive patients with beta-thalassemia major (35 treated with DF and 37 with L1) were studied. The main outcome results were laboratory parameters including determination of the liver iron concentration (LIC) and magnetic resonance imaging (MRI) of the heart and liver. The heart to muscle signal intensity ratios (HSIRs) were significantly incre…

Malemedicine.medical_specialtyLiver Iron ConcentrationPyridonesIronThalassemiaClinical BiochemistryAdministration OralDeferoxamineIron Chelating AgentsGastroenterologychemistry.chemical_compoundInternal medicinemedicineHumansDeferiproneInfusions ParenteralChelation therapyProspective cohort studyGenetics (clinical)medicine.diagnostic_testbusiness.industryMyocardiumbeta-ThalassemiaBiochemistry (medical)Beta thalassemiaMagnetic resonance imagingHematologymedicine.diseaseMagnetic Resonance ImagingDeferoxaminechemistryHeart Function TestsPatient ComplianceFemalebusinessDeferipronemedicine.drugHemoglobin
researchProduct

Multiparametric evaluation of risk factors associated to seroma formation in abdominal wall surgery

2018

INTRODUCTION: Incisional hernia is one of the main topics in the general surgery since there is not a unanimous consensus concerning to the best surgical methodology to adopt. It seems that prosthetic surgery is the best technique, even if responsible for the development of periprosthetic seroma. The aim of this study is to assess whether the preoperative abnormalities of the bio-humoral parameters may be considered as risk factors for seroma. PATIENTS AND METHODS: From July 2016 to July 2017 at the "Policlinico Paolo Giaccone", Palermo, Department of Emergency Surgery, 56 patients included in this study, underwent laparotomic mesh repair. The inclusion criteria were: age > 18 years, inc…

Malemedicine.medical_specialtyMultivariate analysisIncisional herniaPeriprosthetic030230 surgeryRisk AssessmentAbdominal wall03 medical and health sciencesPostoperative Complications0302 clinical medicineRisk Factors030202 anesthesiologymedicineHumansIncisional HerniaAgedUnivariate analysisbusiness.industryAbdominal WallSurgical Meshmedicine.diseaseincisional hernia seroma risk factorsSurgerySettore MED/18 - Chirurgia GeneraleSeromaSurgical meshmedicine.anatomical_structureSeromaOriginal ArticleFemalePeritoneumRisk assessmentbusinessGiornale di Chirurgia - Journal of Surgery
researchProduct

Uptake of [3H]dopamine into dopaminergic and noradrenergic neurones of the isolated neurointermediate lobe of the rat hypophysis. Effects of desipram…

1983

The isolated neurointermediate lobe (NIL) of the rat hypophysis accumulates [3H]dopamine from the incubation medium. Column chromatographic analysis showed that 92% of the tissue radioactivity was contained in the catecholamine fraction. [3H]Dopamine represented 70% and [3H]noradrenaline 30% of the [3H]catecholamines. Desipramine (1 microM) prevented the formation of [3H]noradrenaline without affecting the storage of [3H]dopamine. Nomifensine (10 microM) blocked the storage of [3H]dopamine and [3H]noradrenaline. Thus, in the NIL, [3H]dopamine is taken up into dopaminergic and noradrenergic neurones. In the latter, [3H]dopamine is converted to [3H]noradrenaline, indicating a significant dopa…

Malemedicine.medical_specialtyNomifensineDopamineBiochemistryCellular and Molecular NeuroscienceNorepinephrineNorepinephrinePituitary Gland PosteriorDopamineInternal medicineDesipraminemedicineAnimalsCatecholamine uptakeNeuronsChemistryDopaminergicDesipramineNeurointermediate lobeIsoquinolinesRatsNomifensineEndocrinologyCatecholaminemedicine.drugJournal of neurochemistry
researchProduct

Response of genetically obese Zucker rats to ciprofibrate, a hypolipidemic agent, with peroxisome proliferation activity as compared to Zucker lean a…

1993

Genetically obese Zucker (fa/fa) rats were used as an experimental model to study the effects of hypolipidemic agents on peroxisome proliferation; comparison was made with Zucker lean phenotype (Fa/-) and Sprague-Dawley strain/phenotype. The pharmacokinetics of a single administration of ciprofibrate (1 or 3 mg/kg), appeared to be similar in all strains/phenotypes. After a 2-week oral administration at the same dosages, there were dosage-related increases in hepatocellular peroxisomal yield and in the hepatic enzymes' cyanide-insensitive acyl-CoA oxidase and catalase. The peroxisomal yield was less increased in Zucker than in Sprague-Dawley rats, while the enzyme activities were similarly i…

Malemedicine.medical_specialtyPeroxisome ProliferationBiologyMicrobodiesRats Sprague-Dawleychemistry.chemical_compoundClofibric AcidCytochrome P-450 Enzyme SystemSpecies SpecificityOral administrationReference ValuesInternal medicinemedicineAnimalsObesityEnzyme inducerTriglyceridesHypolipidemic AgentsTriglycerideCholesterolFibric AcidsCell BiologyGeneral MedicinePeroxisomeRatsRats ZuckerIsoenzymesEndocrinologyCholesterolchemistryLiverEnzyme InductionHypolipidemic Agentsbiology.proteinCiprofibratemedicine.drugBiology of the cell
researchProduct

Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins

2012

Loss of muscle mass and function occurs in various diseases. Myostatin blocking can attenuate muscle loss, but downstream signaling is not well known. Therefore, to elucidate associated signaling pathways, we used the soluble activin receptor IIb (sActRIIB-Fc) to block myostatin and activins in mice. Within 2 wk, the treatment rapidly increased muscle size as expected but decreased capillary density per area. sActRIIB-Fc increased muscle protein synthesis 1–2 days after the treatment correlating with enhanced mTORC1 signaling (phosphorylated rpS6 and S6K1, r = 0.8). Concurrently, increased REDD1 and eIF2Bε protein contents and phosphorylation of 4E-BP1 and AMPK was observed. In contrast, pr…

Malemedicine.medical_specialtyPhysiologyEndocrinology Diabetes and MetabolismMuscle ProteinsCell CountP70-S6 Kinase 1MyostatinMechanistic Target of Rapamycin Complex 1Protein Serine-Threonine KinasesBiologyMice03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicinemedicineAnimalsHippo Signaling PathwayExtracellular Signal-Regulated MAP KinasesMuscle Skeletalta315030304 developmental biology0303 health sciencesHippo signaling pathwayMyogenesisTOR Serine-Threonine KinasesSkeletal muscleActivin receptorMyostatinActivinsCapillariesMice Inbred C57BLmedicine.anatomical_structureEndocrinologyHippo signalingMultiprotein ComplexesProtein Biosynthesisbiology.proteinIntercellular Signaling Peptides and ProteinsPhosphorylation030217 neurology & neurosurgerySignal TransductionAmerican Journal of Physiology-Endocrinology and Metabolism
researchProduct

Phosphodiesterase inhibitors suppress alpha2-adrenoceptor-mediated 5-hydroxytryptamine release from tracheae of newborn rabbits.

1998

The outflow of 5-hydroxytryptamine (5-HT) from isolated tracheae of newborn rabbits was determined by high pressure liquid chromatography with electrochemical detection. This 5-HT outflow reflects release from neuroendocrine epithelial cells of the airway mucosa, as previously shown. Phenylephrine, via alpha2B-adrenoceptors, caused a transient increase in 5-HT outflow, maximally by about 250%, an effect mediated by liberation of intracellular Ca2+, as previously shown. The non-selective phosphodiesterase inhibitor 2-isobutyl-1-methylxanthine (IBMX) concentration-dependently inhibited phenylephrine-induced 5-HT release (completely at 100 microM, IC50: 1.3 microM). Likewise, benzafentrine (in…

Malemedicine.medical_specialtySerotoninIBMXSiguazodanPhosphodiesterase InhibitorsPhosphodiesterase 3BiologyEpitheliumchemistry.chemical_compoundCyclic nucleotidePhenylephrineInternal medicine1-Methyl-3-isobutylxanthineQuinoxalinesmedicineAnimalsPhosphodiesterase inhibitorEnzyme InhibitorsPhenylephrineRolipramPharmacologyOxadiazolesPhosphodiesteraseTracheaEndocrinologychemistryAnimals NewbornFemaleRabbitsReceptors Adrenergic beta-2Adrenergic alpha-Agonistsmedicine.drugEuropean journal of pharmacology
researchProduct

Role of thyroid state on induction by ciprofibrate of laurate hydroxylase and peroxisomal enzymes in rat liver microsomes.

1993

The effects of hypothyroidism and hyperthyroidism upon liver microsomal omega-laurate hydroxylase activity (cytochrome P450 IV A1-dependent), peroxisome proliferation marker enzyme activities and acyl CoA oxidase (AOX) expression induced by ciprofibrate (2 mg/kg/day during 8 days) were studied in the male Wistar rat so as to clarify firstly the possible involvement of thyroid hormones in the modification of peroxisomal ciprofibrate-induced enzyme activities in relation to hepatic microsomal cytochrome P450 IV A1 induction, and secondly the possible direct effect of thyroid hormones on the gene expression of specific peroxisomal enzymes. No significant change was found in the ciprofibrate-in…

Malemedicine.medical_specialtyThyroid HormonesPeroxisome ProliferationGlucuronatesGlycerolphosphate DehydrogenaseBiochemistryMicrobodiesMixed Function OxygenasesClofibric AcidCytochrome P-450 Enzyme SystemInternal medicinemedicineAnimalsEnzyme inducerRats WistarPharmacologyTriiodothyroninebiologyBody WeightFibric AcidsCytochrome P450Organ SizePeroxisomeEnoyl-CoA hydrataseRatsEndocrinologyGene Expression RegulationEnzyme InductionProtein Biosynthesisbiology.proteinMicrosomes LiverCiprofibrateCytochrome P-450 CYP4Amedicine.drugHormoneBiochemical pharmacology
researchProduct

Rotarod impairment: catalepsy-like screening test for antipsychotic side effects.

2009

Extrapyramidal motoric symptoms are casual side effects under antipsychotic medication. New generation antipsychotics are expected to have a reduced risk due to different receptor affinities. Here, haloperidol and the new generation antipsychotics, risperidone, amisulpride, and aripiprazole, were examined with both catalepsy test and rotarod performance test to screen for their usability in mice. Mice treated with haloperidol, risperidone, and aripiprazole showed dose and time-dependent impairment. Amisulpride-treated mice showed no signs of catalepsy. Catalepsy test and rotarod performance test were useful methods to detect side effects of both generation antipsychotics. Catalepsy test pro…

Malemedicine.medical_specialtyTime FactorsScreening testmedicine.medical_treatmentStatistics as TopicDrug Evaluation PreclinicalCatalepsyPharmacologyMotor ActivityRotarod performance testMiceBasal Ganglia DiseasesmedicineHaloperidolAnimalsAmisulprideAntipsychoticPsychiatryFreezing Reaction CatalepticRisperidoneDose-Response Relationship DrugGeneral NeuroscienceGeneral Medicinemedicine.diseaseDisease Models AnimalRotarod Performance TestAripiprazolePsychologymedicine.drugAntipsychotic AgentsThe International journal of neuroscience
researchProduct

Delayed effects of ciprofibrate on rat liver peroxisomal properties and proto-oncogene expression.

1995

Peroxisome proliferators (PPs) are non-genotoxic carcinogens in rodents. Their reversible effects on rat liver have been studied with ciprofibrate and fenofibrate. We found that with the hypolipemic drug fenofibrate a pause of 28 days is sufficient for a return to normal status, whereas with the highly potent PP ciprofibrate, the stimulation of ACO mRNA levels remains after its withdrawal. We investigated the effects of the renewal of the treatment with PPs on other peroxisomal parameters and proto-oncogene expression using Wistar rats. Interestingly, c-myc expression was enhanced even upon drug withdrawal, and was more stimulated by the second exposure to ciprofibrate, while c-fos expressi…

Malemedicine.medical_specialtyTime FactorseducationStimulationMitochondria LiverBiologyBiochemistryMicrobodiesDrug withdrawalClofibric AcidFenofibrateInternal medicineProto-Oncogene ProteinsGene expressionmedicineAnimalsRats WistarCarcinogenPharmacologyFenofibrateOncogeneFibric AcidsPeroxisomemedicine.diseaseRatsEndocrinologyLiverMicrosomes LiverCiprofibrateAcyl-CoA OxidaseOxidoreductasesmedicine.drugBiochemical pharmacology
researchProduct

Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Elutin…

2009

Objectives: We sought to evaluate the safety and performance of the Janus Tacrolimus-Eluting stent (TES) in an unselected population of patients, without application of restrictive clinical or angiographic criteria. Background: Continued attention to the safety, efficacy, and deliverability of first-generation drug eluting stents has led to the development of new antiproliferative agents with alternative stent platforms and different drug carrier vehicles. Methods: The TEST (Tacrolimus Eluting STent) registry is a prospective, nonrandomized single-center registry in which 140 consecutive patients who underwent single- or multi-vessel percutaneous coronary intervention between February 2005 …

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulationMyocardial InfarctionRestenosiKaplan-Meier EstimateCoronary AngiographyProsthesis DesignRisk AssessmentTacrolimusCoronary RestenosisRestenosismedicineHumansRadiology Nuclear Medicine and imagingMyocardial infarctionProspective StudiesRegistriesAngioplasty Balloon CoronaryeducationAgededucation.field_of_studybusiness.industryCoronary StenosisStentPercutaneous coronary interventionTacrolimus eluting stent.Cardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseTacrolimusSurgeryTreatment OutcomeAntiproliferative AgentsFemaleRadiologySafetyCardiology and Cardiovascular MedicinebusinessMaceCatheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions
researchProduct